MedTech Dive January 23, 2024
After reporting growth for its procedure-based units in the fourth quarter, J&J forecast surgery volumes to be above pre-pandemic levels this year.
Johnson & Johnson’s surgery and orthopedic units had solid growth to close out 2023 as procedure volumes remained stable after COVID-19 declines, potentially signaling positive reports from other procedure-dependent medical device companies this earnings season.
The healthcare giant, which typically reports early in the season and can be a bellwether for companies like Boston Scientific, Medtronic and Stryker, expects procedure volumes to remain above pre-pandemic levels for all of 2024.
CEO Joaquin Duato told investors on a Tuesday earnings call that the COVID-19 impact has stabilized globally, though the company is still being affected by macroeconomic challenges like...
Today's Sponsors
Today's Sponsor